Tag: sage therapeutics
December 23, 2019
Pharma Trends 2019: FDA Approvals Make Waves Through Market
INN takes a look at the pharma trends of 2019 that have shaken up the space this year and created...
March 20, 2019
Sage Therapeutics Wins First Postpartum Depression Drug Approval
The US Food and Drug Administration regards Sage Therapeutics' drug Zulresso as a breakthrough therapy to treat postpartum depression. November 6, 2018
Sage Therapeutics Announces Third Quarter 2018 Financial Results
Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported... June 12, 2018
Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meetin
Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced...
April 30, 2018
Key Stock Catalysts in the FDA Drug Application Process
Pharmaceutical and biotech companies in the US must follow a standard process to advance a new drug candidate through nonclinical... September 27, 2016